Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
Open Access
Abstract
Background: Combined immunotherapy has significantly improved survival of patients with advanced melanoma, but there are still patients that do not benefit from it. Early biomarkers that indicate potential resistance would be highly relevant for these patients. Methods: We comprehensively analyzed tumor and blood samples from patients with advanced melanoma, treated with combined immunotherapy and performed descriptive and survival analysis. Results: Fifty-nine patients with a median follow-up of 13 months (inter quartile range (IQR) 11–15) were included. Interestingly, nine patients were found to have pathogenic or likely pathogenic (P/LP) germline variants in one of these genes: BRCA2, POLE, WRN, FANCI, CDKN2A, BAP1, PALB2 and RAD54B. Most of them are involved in DNA repair mechanisms. Patients with P/LP germline variants had a significantly shorter progression-free survival (PFS) and melanoma specific survival (MSS) compared to patients without P/LP germline variants (HR = 2.16; 95% CI: 1.01–4.64; p = 0.048 and HR = 3.21; 95% CI: 1.31–7.87; p = 0.011, respectively). None of the patients with a P/LP germline variant responded to combined immunotherapy. In the multivariate Cox-regression analysis, presence of a P/LP germline variant, S100B and lactate dehydrogenase (LDH) remained independently significant factors for MSS (p = 0.036; p = 0.044 and p = 0.001, respectively). Conclusions: The presence of P/LP germline variants was associated with resistance to combined immunotherapy in our cohort. As genes involved in DNA repair mechanisms are also involved in lymphocyte development and T-cell differentiation, a P/LP germline variant in these genes may preclude an antitumor immune response.Keywords
Funding Information
- TÜFF Habilitation Program for Women of the Faculty of Medicine Tuebingen (2521-0-0)
- Bundesministerium für Forschung, Technologie und Raumfahrt (KMU-innovative initiative)
This publication has 57 references indexed in Scilit:
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyThe Lancet Oncology, 2019
- Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicAnnals of Oncology, 2018
- Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine studyGenetics in Medicine, 2017
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid TumorsJAMA Oncology, 2016
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificityNature Biotechnology, 2015
- The Sequence of the Human GenomeScience, 2001
- Initial sequencing and analysis of the human genomeNature, 2001